MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: SignaBlok, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Awarded NIH Grant to Develop New Nanotechnology for Diagnostic Imaging of Atherosclerosis - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis
SignaBlok Awarded NIH Grant to Develop New Nanotechnology for Diagnostic Imaging of Atherosclerosis

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2012/07/10 - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

SignaBlok, Inc., a Massachusetts-based emerging biopharmaceutical company, announced today the award of a Small Business Innovation Research (SBIR) grant by the National Heart Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This project, entitled “Multifunctional nanoformulations for diagnostic imaging of atherosclerosis”, will explore the use of SignaBlok’s targeted nanoparticles as a safe and efficient delivery platform for imaging of the most dangerous type of arterial plaques – called unstable (vulnerable) plaques – in early diagnosis and treatment of atherosclerosis. Research will be conducted in conjunction with the Advanced Magnetic Resonance Imaging (MRI) Center at the University of Massachusetts Medical School, Worcester.

SignaBlok’s proprietary nanosystem for delivery of drugs and imaging agents targets macrophages, inflammatory cells that are critically involved in plaque formation and have a high discriminatory power to identify the vulnerable plaque. The goal of this grant is to validate a novel approach to macrophage-targeted delivery of MRI contrast agents in a clinically relevant animal model of atherosclerosis.

“We are extremely pleased by the award of this SBIR grant from the NHLBI/NIH,” said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. “The proposed research will result in the development of novel imaging techniques that would fill an important unmet medical need in the diagnosis and treatment of atherosclerosis. This would offer better way to identify high-risk individuals, provide earlier diagnosis before symptoms occur and monitor treatment effects.”

“Macrophages are important imaging targets for diagnosis and image-guided therapy of not only atherosclerosis but also cancer. Thus, this grant gives us an opportunity to develop targeted nanosystem for in vivo macrophage imaging with a wide range of clinical applications,” said Alexander Sigalov.

About atherosclerosis: Atherosclerosis (hardening of the arteries) is the major cause of cardiovascular disease, the number one leading cause of death worldwide. There are two broad categories of atherosclerotic plaques: stable and unstable (also called vulnerable). A vast majority of cardiovascular events such as stroke or myocardial infarction result from rupture or erosion of vulnerable plaques. Accurate in vivo tracking of plaque vulnerability and progression using non-invasive imaging approaches allows early identification of high-risk patients as well as facilitates early intervention decision-making process and monitoring of the effectiveness of interventions.

About SignaBlok
SignaBlok (signablok.com) is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Awarded NIH Grant to Develop New Nanotechnology for Diagnostic Imaging of Atherosclerosis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa
Global Biosimilars Market Poised to Grow At Chart-topping Levels with a CAGR of 17.3%, Reaching .2 Billion by 2026 Finds Frost & Sullivan
Technological Advancements in Manufacturing Boost the Cell and Gene Therapy Market Says Frost & Sullivan
Huami Corp and Royal DSM Announce Collaboration on Wearable Technologies and Health Tracking for Personalized Nutrition
DSM Expands Animal Nutrition & Health Operations in China with Opening of Seventh Premix Plant
Biosurfactants and Natural Preservatives Drive Innovation for Functional Ingredients in Personal Care Market Finds Frost & Sullivan
Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors
DSM Unveils Purpose-led Brand Strategy Marking Transition to End-to-end Partner in Nutrition and Health
Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)